Claims for Patent: 8,865,881

Summary for Patent: 8,865,881

Title:	Delivery of proteins using adeno-associated virus (AAV) vectors
Abstract:	Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.
Inventor(s):	Balazs; Alejandro Benjamin (Berkeley, CA), Baltimore; David (Pasadena, CA)
Assignee:	California Institute of Technology (Pasadena, CA)
Application Number:	13/400,945
Patent Claims:	1. A viral vector, comprising: a 5' inverted terminal repeat (ITR) of adeno-associated virus (AAV) and a 3' AAV ITR; a synthetic promoter, wherein the promoter comprises a nucleotide sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 1; a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins of interest, and a posttranscriptional regulatory element downstream of the restriction site, wherein the promoter, the restriction site and the posttranscriptional regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR. 2. The viral vector of claim 1, further comprising a polynucleotide inserted at the restriction site and operably linked with the promoter, wherein the polynucleotide comprises a coding region of a protein of interest. 3. The viral vector of claim 2, wherein the polynucleotide comprises a signal peptide-encoding sequence immediately upstream of the coding region of the protein of interest. 4. The viral vector of claim 3, wherein the signal peptide is selected from the group consisting of a signal peptide of interferon, a signal peptide of human growth hormone, a signal peptide of erythropoietin (EPO), a signal peptide of granulocyte colony-stimulating factor (G-CSF), a signal peptide of insulin, and any combination thereof. 5. The viral vector of claim 2, wherein the vector comprises a nucleotide sequence having at least 70% sequence identity to the Kozak consensus sequence. 6. The viral vector of claim 1, wherein the protein of interest is selected from the group consisting of full-length antibodies, growth hormones (GHs), insulin-like growth factors (IGFs), G-CSFs, erythropoietins (EPOs), insulins, antibody Fab fragments, antibody scFV fragments, hemophilia related clotting proteins, dystrophin, lysosomal acid lipase, phenylalanine hydroxylase (PAH), glycogen storage disease-related enzymes, and any variants thereof. 7. The viral vector of claim 1, wherein the protein of interest is a virus neutralizing antibody. 8. The viral vector of claim 7, wherein the virus neutralizing antibody is a neutralizing antibody for a human immunodeficiency virus (HIV), a hepatitis C virus (HCV), or an influenza virus. 9. The viral vector of claim 8, wherein the neutralizing antibody for HIV is selected from the group consisting of b12 anti-HIV antibody, 2G12 anti-HIV antibody, 4E10 anti-HIV antibody, 2F5 anti-HIV antibody, and any variant thereof. 10. The viral vector of claim 8, wherein the neutralizing antibody for HCV is selected from the group consisting AR3A anti-HCV antibody, AR3B anti-HCV antibody, AR4A anti-HCV antibody, and any variant thereof. 11. The viral vector of claim 1, wherein the protein of interest is a neutralizing antibody for malaria. 12. The viral vector of claim 1, wherein the promoter comprises a splice donor, a splice acceptor, or any variant thereof. 13. The viral vector of claim 12, wherein the splice donor comprises a nucleotide sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 5. 14. The viral vector of claim 12, wherein the splice acceptor comprises a nucleotide sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 6. 15. The viral vector of claim 1, wherein the promoter comprises a nucleotide sequence having at least 95% sequence identity to the sequence of any one of SEQ ID NOs: 2-4. 16. The viral vector of claim 1, wherein the posttranscriptional regulatory element is a viral posttranscriptional regulatory element. 17. The viral vector of claim 16, wherein the viral posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), hepatitis B virus posttranscriptional regulatory element (HBVPRE), RNA transport element (RTE), or any variant thereof. 18. The viral vector of claim 1, further comprising a transcription termination region downstream of the posttranscriptional regulatory element. 19. The viral vector of claim 18, the transcription termination region comprises an SV40 late poly(A) sequence, a rabbit beta-globin poly(A) sequence, a bovine growth hormone poly(A) sequence, or any variant thereof. 20. The viral vector of claim 1, wherein the promoter comprises an intron. 21. The viral vector of claim 20, wherein the intron is a synthetic intron comprising a nucleotide sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 8. 22. The viral vector of claim 2, wherein the polynucleotide comprises a first coding region for the heavy chain variable region of an immunoglobulin and a second coding region for the light chain variable region of the immunoglobulin. 23. The viral vector of claim 22, wherein the first coding region and the second coding region are separated by a 2A sequence. 24. The viral vector of claim 23, wherein the 2A sequence is a foot-and-mouth disease virus 2A (F2A) sequence. 25. The viral vector of claim 22, wherein 5' of the first coding region is fused with a first signal peptide sequence and 5' of the second coding region is fused with a second signal peptide sequence. 26. The viral vector of claim 25, wherein the first signal peptide sequence and the second signal peptide sequence are different. 27. The viral vector of claim 1, wherein the region starting from the 5' ITR and ending at the 3' ITR is at least 2.5 kb. 28. An isolated, synthetic or recombinant polynucleotide, comprising: a nucleic acid sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 1. 29. The polynucleotide of claim 28, wherein the polynucleotide comprises the nucleotide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.

Details for Patent 8,865,881

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-02-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-02-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-02-22